Noxopharm Ltd (ASX: NOX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Noxopharm Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $21.92 million
P/E Ratio 32.89
Dividend Yield 0.00%
Shares Outstanding 292.24 million
Earnings per share -0.041
Dividend per share N/A
Year To Date Return 4.23%
Earnings Yield 3.04%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Noxopharm Ltd (ASX: NOX)
    Latest News

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Share Gainers

    Why Noxopharm, Orora, Ramelius, and Silver Lake shares are pushing higher

    Not all shares are falling with the market on Wednesday.

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    ASX healthcare stock Noxopharm explodes 165% on FDA news

    Shareholders of this healthcare stock will be smiling today. Here's why.

    Read more »

    Lab worker puts hands in the air and dances around
    Healthcare Shares

    This ASX healthcare share is surging 17% on a new FDA ruling

    Biotechnology company Noxopharm has provided some good news about one of its drugs.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Earnings Results

    Clinical trials not enough to stop Noxopharm (ASX:NOX) shares' 5% plunge on Monday

    The Noxopharm share price closed in the red on Monday as the company released its financial results for the half…

    Read more »

    Two lab technicians wearing white coats discuss results they see on a computer screen.
    Share Market News

    The Noxopharm (ASX:NOX) share price is jumping 6% after announcing a new CEO

    Shares in the ASX biopharm company are rallying this morning.

    Read more »

    A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
    Healthcare Shares

    Here's why the Noxopharm (ASX: NOX) share price leapt 7% today

    The drug development comany has reported on its clinical trial for cancer treatment.

    Read more »

    medical research laboratory assistant examines solutions in test tubes
    Share Gainers

    Why is the Noxopharm (ASX:NOX) share price up 4% on Monday?

    There's more clinical trial momentum out of the drug developer's corner today.

    Read more »

    elderly woman cheers in doctor's office
    Share Gainers

    Noxopharm (ASX:NOX) share price jumps 13% on COVID treatment update

    This drug development company's shares are racing higher today...

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Healthcare Shares

    The Noxopharm (ASX:NOX) share price is soaring 7%

    Shares in the Australian drug development company are flying after a positive notification.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Healthcare Shares

    Noxopharm (ASX:NOX) share price edges lower after clinical trial update

    The clinical-stage drug development company's shares have taken a tumble today

    Read more »

    Rising healthcare ASX share price represented by doctor giving thumbs up
    Share Gainers

    Why the Noxopharm (ASX:NOX) share price is charging higher again

    This clinical-stage drug development company just got some good news...

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Why the Noxopharm share price rocketed 22% today

    The biotech company's shares bolted today on good news out of its current trial. Here's a closer look.

    Read more »

    NOX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Noxopharm Ltd

    Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

    NOX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.07 $0.00 0.00% 211,814 $0.07 $0.08 $0.07
    22 May 2024 $0.08 $0.01 14.08% 101,106 $0.07 $0.08 $0.07
    21 May 2024 $0.07 $0.00 0.00% 36,000 $0.07 $0.07 $0.07
    17 May 2024 $0.07 $-0.01 -12.82% 665,965 $0.08 $0.08 $0.07
    15 May 2024 $0.08 $0.01 14.71% 452,444 $0.07 $0.08 $0.07
    14 May 2024 $0.07 $0.01 15.87% 259,868 $0.06 $0.07 $0.06
    13 May 2024 $0.06 $0.00 0.00% 175,209 $0.06 $0.06 $0.06
    10 May 2024 $0.06 $0.00 0.00% 72,785 $0.06 $0.06 $0.06
    09 May 2024 $0.06 $0.00 0.00% 269,539 $0.06 $0.06 $0.06
    08 May 2024 $0.06 $0.00 0.00% 146,058 $0.06 $0.06 $0.06
    07 May 2024 $0.06 $0.00 0.00% 6,966 $0.06 $0.06 $0.06
    06 May 2024 $0.06 $0.00 0.00% 23,374 $0.07 $0.07 $0.06
    03 May 2024 $0.06 $0.00 0.00% 353,031 $0.06 $0.06 $0.06
    02 May 2024 $0.06 $-0.01 -14.71% 211,000 $0.07 $0.07 $0.06
    01 May 2024 $0.07 $0.00 0.00% 79,699 $0.07 $0.07 $0.07
    30 Apr 2024 $0.07 $0.00 0.00% 49,289 $0.07 $0.07 $0.07
    29 Apr 2024 $0.07 $0.00 0.00% 19,895 $0.07 $0.07 $0.07

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Sep 2023 Frederick (Fred) Bart Buy 880 $30
    On-market trade.
    14 Sep 2023 Frederick (Fred) Bart Buy 253,001 $9,108
    On-market trade.
    30 Jun 2023 Frederick (Fred) Bart Buy 135,281 $5,681
    On-market trade.
    29 Jun 2023 Frederick (Fred) Bart Transfer 3,080,189 $170,950
    Off-market transfer.
    29 Jun 2023 Frederick (Fred) Bart Transfer 3,080,189 $170,950
    Off-market transfer.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Frederick (Fred) Bart Non-Executive DirectorNon-Executive Chairman May 2020
    Mr Bart was appointed the Managing Director of Textile Industries Australia In 1985,. The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets. In 2013, Mr Bart became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers. He is a member of Risk Committee.
    Mr Peter Ashley Marks Non-Executive DirectorNon-Executive Deputy Chairman Mar 2016
    Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPO's, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a range of transactions with a focus in the life-sciences, biotechnology, medical technology and high tech as well as the mining sector. Peter has served as both an Executive and Non-Executive Director of a number of different entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of Risk Committee.
    Mr Boris Patkin Non-Executive Director Mar 2020
    Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. As a financial and investment advisor, Boris has an understanding of industry trends and has insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also a business consultant in the medical and disruptive technology arena. He is currently a member of MeSAFAA and is a senior advisor with Morgans Financial Ltd. He is also non-executive chairman of Ausmon Resources Ltd - since 2014. He is member of Risk Committee.
    Dr Gisela Mautner Chief Executive OfficerManaging Director Feb 2022
    Dr Mautner has more than 20 years of experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.
    Mr David James Franks Company Secretary Jan 2017
    David James Franks Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(i) 26,249,106 8.98%
    Mrs Eleanore Goodridge 13,050,000 4.47%
    Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(ii) 8,000,000 2.74%
    Citicorp Nominees 6,751,024 2.31%
    Rgt Capital Fund No 5 (Noxo) Pty Ltd 6,500,333 2.22%
    Mr Fred Bart 5,618,651 1.92%
    Link Traders (Aust) Pty Ltd(i) 5,545,298 1.90%
    Link Traders (Aust) Pty Ltd (ii) 5,041,224 1.73%
    Kale Capital Corporation Limited 4,997,437 1.71%
    Jamber Investments Pty Ltd (The Amber Schwarz Fam A/C) 4,252,761 1.46%
    Rhlc Pty Limited (Rhlc S/F A/C) 3,200,000 1.09%
    Mr Lizhong Yu 2,918,000 1.00%
    Blackcourt (Nsw) Pty Limited (Lawsam Super Fund A/C) 2,686,376 0.92%
    Mr Robert Thomas Lin 2,500,000 0.86%
    Ogen Nominees Pty Ltd 2,300,000 0.79%
    Halcyon Nominees Pty Ltd (Halcyon Super Fund A/C) 2,000,000 0.68%
    Mrs Sophie Ethel Gelski 1,942,424 0.66%
    Helium Management Pty Ltd (Helium S/F A/C) 1,751,246 0.60%
    Mr Michael Shabat & Ms Meital Hana Shabat (M&M Shabat Super Fund A/C) 1,702,824 0.58%
    Berne No 132 Nominess Pty Ltd (331898 A/C) 1,660,238 0.57%